BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29440769)

  • 1. Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).
    Chae YK; Chang S; Ko T; Anker J; Agte S; Iams W; Choi WM; Lee K; Cruz M
    Sci Rep; 2018 Feb; 8(1):2918. PubMed ID: 29440769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
    Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
    Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
    Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB.
    Liu W; Wang H; Bai F; Ding L; Huang Y; Lu C; Chen S; Li C; Yue X; Liang X; Ma C; Xu L; Gao L
    Cell Prolif; 2020 Mar; 53(3):e12776. PubMed ID: 32020709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.
    Ortiz-Cuaran S; Swalduz A; Foy JP; Marteau S; Morel AP; Fauvet F; De Souza G; Michon L; Boussageon M; Gadot N; Godefroy M; Léon S; Tortereau A; Mourksi NE; Leonce C; Albaret MA; Dongre A; Vanbervliet B; Robert M; Tonon L; Pommier RM; Hofman V; Attignon V; Boyault S; Audoynaud C; Auclair J; Bouquet F; Wang Q; Ménétrier-Caux C; Pérol M; Caux C; Hofman P; Lantuejoul S; Puisieux A; Saintigny P
    Eur J Cancer; 2022 Jul; 169():106-122. PubMed ID: 35550950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.
    Chae YK; Choi WM; Bae WH; Anker J; Davis AA; Agte S; Iams WT; Cruz M; Matsangou M; Giles FJ
    Sci Rep; 2018 Jan; 8(1):1023. PubMed ID: 29348685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC.
    Yin H; Wang Y; Chen W; Zhong S; Liu Z; Zhao J
    Gene; 2016 Dec; 594(1):23-29. PubMed ID: 27581786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
    Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
    BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer.
    Tong X; Wang S; Lei Z; Li C; Zhang C; Su Z; Liu X; Zhao J; Zhang HT
    Oncogene; 2020 Apr; 39(14):2890-2904. PubMed ID: 32029901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
    Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
    Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
    Tian Y; Wang J; Wen Q; Su G; Sun Y
    Aging (Albany NY); 2021 May; 13(9):12691-12709. PubMed ID: 33973529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer.
    Li C; Wan L; Liu Z; Xu G; Wang S; Su Z; Zhang Y; Zhang C; Liu X; Lei Z; Zhang HT
    Cancer Lett; 2018 Apr; 418():185-195. PubMed ID: 29339211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.
    Wang L; Yang H; Lei Z; Zhao J; Chen Y; Chen P; Li C; Zeng Y; Liu Z; Liu X; Zhang HT
    Oncogene; 2016 Feb; 35(7):867-77. PubMed ID: 25961934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer.
    Tischler V; Pfeifer M; Hausladen S; Schirmer U; Bonde AK; Kristiansen G; Sos ML; Weder W; Moch H; Altevogt P; Soltermann A
    Mol Cancer; 2011 Oct; 10():127. PubMed ID: 21985405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.